Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial

Introduction A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the health...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bruce Kirenga, Andrew Nunn, Ewan Tomeny, Jason Madan, Bertel Squire, Laura Rosu, Eve Worrall, Mamo Girma, Vanita Patel, Makwana Mukesh, Malaisamy Muniyandi, Shravan Kumar, Sangeetha Subramani, Saleem Ahmad, Jasper Nidoi, Irina Pirlog, Mariana Macarie, ID Rusen, Gay Bronson, Meera Gurumurthy, Karen Sanders, Sarah Meredith, Wendy Dodds Ben Spittle, Robyn Henry-Cockles, Rachel Bennett, Elisa Giallongo, Danni Maas, Ruth Goodall, Saiam Ahmed, Claire Cook, Katharine Bellenger, Gopalan Narendran, Elena Tudor, Rajesh Solanki, Daniel Meressa, Adamu Bayissa, Anuj Bhatnagar
Formato: article
Lenguaje:EN
Publicado: BMJ Publishing Group 2020
Materias:
R
Acceso en línea:https://doaj.org/article/a9fcc9bd4f9a4b70a682711333f0f708
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a9fcc9bd4f9a4b70a682711333f0f708
record_format dspace
spelling oai:doaj.org-article:a9fcc9bd4f9a4b70a682711333f0f7082021-11-20T14:00:06ZEconomic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial10.1136/bmjopen-2020-0423902044-6055https://doaj.org/article/a9fcc9bd4f9a4b70a682711333f0f7082020-12-01T00:00:00Zhttps://bmjopen.bmj.com/content/10/12/e042390.fullhttps://doaj.org/toc/2044-6055Introduction A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the health system. STREAM is the first randomised controlled trial with an economical evaluation to compare all-oral and injectable-containing 9–11-month MDR-TB treatment regimens.Methods and analysis Health system costs of delivering a 9-month injectable-containing regimen and a 9-month all-oral bedaquiline-containing regimen will be collected in Ethiopia, India, Moldova and Uganda, using ‘bottom-up’ and ‘top-down’ costing approaches. Patient costs will be collected using questionnaires that have been developed based on the STOP-TB questionnaire. The primary objective of the study is to estimate the cost utility of the two regimens, from a health system perspective. Secondary objectives include estimating the cost utility from a societal perspective as well as evaluating the cost-effectiveness of the regimens, using both health system and societal perspectives. The effect measure for the cost–utility analysis will be the quality-adjusted life years (QALY), while the effect measure for the cost-effectiveness analysis will be the efficacy outcome from the clinical trial.Ethics and dissemination The study has been evaluated and approved by the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease and also approved by ethics committees in all participating countries. All participants have provided written informed consent. The results of the economic evaluation will be published in a peer-reviewed journal.Trial registration number ISRCTN18148631.Bruce KirengaAndrew NunnEwan TomenyJason MadanBertel SquireLaura RosuEve WorrallMamo GirmaVanita PatelMakwana MukeshMalaisamy MuniyandiShravan KumarSangeetha SubramaniSaleem AhmadJasper NidoiIrina PirlogMariana MacarieID RusenGay BronsonMeera GurumurthyKaren SandersSarah MeredithWendy Dodds Ben SpittleRobyn Henry-CocklesRachel BennettElisa GiallongoDanni MaasRuth GoodallSaiam AhmedClaire CookKatharine BellengerGopalan NarendranElena TudorRajesh SolankiDaniel MeressaAdamu BayissaAnuj BhatnagarBMJ Publishing GrouparticleMedicineRENBMJ Open, Vol 10, Iss 12 (2020)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
spellingShingle Medicine
R
Bruce Kirenga
Andrew Nunn
Ewan Tomeny
Jason Madan
Bertel Squire
Laura Rosu
Eve Worrall
Mamo Girma
Vanita Patel
Makwana Mukesh
Malaisamy Muniyandi
Shravan Kumar
Sangeetha Subramani
Saleem Ahmad
Jasper Nidoi
Irina Pirlog
Mariana Macarie
ID Rusen
Gay Bronson
Meera Gurumurthy
Karen Sanders
Sarah Meredith
Wendy Dodds Ben Spittle
Robyn Henry-Cockles
Rachel Bennett
Elisa Giallongo
Danni Maas
Ruth Goodall
Saiam Ahmed
Claire Cook
Katharine Bellenger
Gopalan Narendran
Elena Tudor
Rajesh Solanki
Daniel Meressa
Adamu Bayissa
Anuj Bhatnagar
Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
description Introduction A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-containing regimens, for both the patient and the health system. STREAM is the first randomised controlled trial with an economical evaluation to compare all-oral and injectable-containing 9–11-month MDR-TB treatment regimens.Methods and analysis Health system costs of delivering a 9-month injectable-containing regimen and a 9-month all-oral bedaquiline-containing regimen will be collected in Ethiopia, India, Moldova and Uganda, using ‘bottom-up’ and ‘top-down’ costing approaches. Patient costs will be collected using questionnaires that have been developed based on the STOP-TB questionnaire. The primary objective of the study is to estimate the cost utility of the two regimens, from a health system perspective. Secondary objectives include estimating the cost utility from a societal perspective as well as evaluating the cost-effectiveness of the regimens, using both health system and societal perspectives. The effect measure for the cost–utility analysis will be the quality-adjusted life years (QALY), while the effect measure for the cost-effectiveness analysis will be the efficacy outcome from the clinical trial.Ethics and dissemination The study has been evaluated and approved by the Ethics Advisory Group of the International Union Against Tuberculosis and Lung Disease and also approved by ethics committees in all participating countries. All participants have provided written informed consent. The results of the economic evaluation will be published in a peer-reviewed journal.Trial registration number ISRCTN18148631.
format article
author Bruce Kirenga
Andrew Nunn
Ewan Tomeny
Jason Madan
Bertel Squire
Laura Rosu
Eve Worrall
Mamo Girma
Vanita Patel
Makwana Mukesh
Malaisamy Muniyandi
Shravan Kumar
Sangeetha Subramani
Saleem Ahmad
Jasper Nidoi
Irina Pirlog
Mariana Macarie
ID Rusen
Gay Bronson
Meera Gurumurthy
Karen Sanders
Sarah Meredith
Wendy Dodds Ben Spittle
Robyn Henry-Cockles
Rachel Bennett
Elisa Giallongo
Danni Maas
Ruth Goodall
Saiam Ahmed
Claire Cook
Katharine Bellenger
Gopalan Narendran
Elena Tudor
Rajesh Solanki
Daniel Meressa
Adamu Bayissa
Anuj Bhatnagar
author_facet Bruce Kirenga
Andrew Nunn
Ewan Tomeny
Jason Madan
Bertel Squire
Laura Rosu
Eve Worrall
Mamo Girma
Vanita Patel
Makwana Mukesh
Malaisamy Muniyandi
Shravan Kumar
Sangeetha Subramani
Saleem Ahmad
Jasper Nidoi
Irina Pirlog
Mariana Macarie
ID Rusen
Gay Bronson
Meera Gurumurthy
Karen Sanders
Sarah Meredith
Wendy Dodds Ben Spittle
Robyn Henry-Cockles
Rachel Bennett
Elisa Giallongo
Danni Maas
Ruth Goodall
Saiam Ahmed
Claire Cook
Katharine Bellenger
Gopalan Narendran
Elena Tudor
Rajesh Solanki
Daniel Meressa
Adamu Bayissa
Anuj Bhatnagar
author_sort Bruce Kirenga
title Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
title_short Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
title_full Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
title_fullStr Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
title_full_unstemmed Economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the STREAM trial
title_sort economic evaluation protocol of a short, all-oral bedaquiline-containing regimen for the treatment of rifampicin-resistant tuberculosis from the stream trial
publisher BMJ Publishing Group
publishDate 2020
url https://doaj.org/article/a9fcc9bd4f9a4b70a682711333f0f708
work_keys_str_mv AT brucekirenga economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT andrewnunn economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT ewantomeny economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT jasonmadan economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT bertelsquire economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT laurarosu economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT eveworrall economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT mamogirma economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT vanitapatel economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT makwanamukesh economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT malaisamymuniyandi economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT shravankumar economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT sangeethasubramani economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT saleemahmad economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT jaspernidoi economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT irinapirlog economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT marianamacarie economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT idrusen economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT gaybronson economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT meeragurumurthy economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT karensanders economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT sarahmeredith economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT wendydoddsbenspittle economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT robynhenrycockles economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT rachelbennett economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT elisagiallongo economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT dannimaas economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT ruthgoodall economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT saiamahmed economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT clairecook economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT katharinebellenger economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT gopalannarendran economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT elenatudor economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT rajeshsolanki economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT danielmeressa economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT adamubayissa economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
AT anujbhatnagar economicevaluationprotocolofashortalloralbedaquilinecontainingregimenforthetreatmentofrifampicinresistanttuberculosisfromthestreamtrial
_version_ 1718419442437718016